Group 1 - The company, Hongli Medical Management (09906.HK), will hold a board meeting on August 29, 2025, to consider and approve the interim results for the six months ending June 30, 2025, and to discuss the potential distribution of an interim dividend, if any [1] - The company has issued a profit warning, expecting a net loss attributable to shareholders not to exceed 2 million [1]

（ 於開曼群島註冊成立的有限公司） （股份代號：9906） 董事會會議召開日期 宏力醫療管理集團有限公司（「本公司」連同其附屬公司，「本集團」）董事會 （「董事會」）謹此宣佈，本公司將於二零二五年八月二十九日（ 星期五 ）舉行 董事會會議，藉以（ 其中包括 ）考慮及通過本集團截至二零二五年六月三十 日 止六 個月 的中 期業 績及 發佈 ，並 考慮 派發 中期 股息（ 如 有 ），以 及處 理其 他事項。 承董事會命 香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 對因 本 公 告全 部 或 任 何 部份 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致的 任 何 損 失承 擔任何責任。 Honliv Healthcare Management Group Company Limited 宏 力 醫 療 管 理 集 團 有 限 公 司 董事長 秦岩 香港，二零二五年八月十九日 於 本 公告 日 期 ， 董 事會 成 員 包 ...

Core Viewpoint - Macro Medical Management (09906) anticipates a net loss attributable to shareholders not exceeding RMB 2 million for the six months ending June 30, 2025, compared to a net profit of approximately RMB 20 million for the six months ending June 30, 2024 [1] Group 1 - The expected shift from profit to loss is primarily due to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rate from the public medical insurance plan for the fiscal year 2024, completed in May 2025, was lower than the estimated settlement rate used in the consolidated financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company further adjusted the estimated settlement rate for inpatient service revenue covered by the plan for the first half of 2025 downward due to the aforementioned discrepancies [1]

Core Viewpoint - The company expects to report a net loss attributable to shareholders of no more than RMB 2 million for the six months ending June 30, 2025, a significant decline from a net profit of approximately RMB 20 million for the same period in 2024 [1] Group 1: Financial Performance - The anticipated shift from profit to loss is primarily attributed to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rate from the 2024 public medical insurance plan, completed in May 2025, was lower than the estimated settlement rate used in the financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company has further adjusted the estimated settlement rate for inpatient service revenue covered by the plan for the first half of 2025 downward [1]

Core Viewpoint - The company, Hongli Medical Management, anticipates a net loss attributable to shareholders of no more than RMB 2 million for the six months ending June 30, 2025, a significant decline from a net profit of approximately RMB 20 million for the same period in 2024 [1] Group 1: Financial Performance - The expected shift from profit to loss is primarily attributed to a decrease in demand for inpatient medical services, leading to reduced revenue [1] - The actual settlement rates from the public medical insurance plan for the fiscal year 2024, completed in May 2025, were lower than the estimated settlement rates used in the consolidated financial statements for the year ending December 31, 2024, resulting in decreased inpatient service revenue [1] - The company further adjusted the estimated settlement rates for inpatient service revenue covered by the plan for the first half of 2025 downward due to the aforementioned discrepancies [1]

董事 會認 為上 述預 期由 盈轉 虧的 情況 主要是 由於 (i)住 院醫 療服 務的 需求減 少導致收入減少；及(ii)根據二零二五年五月完成的二零二四年度公共醫療 保 險 計劃 清 算 結 果 ，該 等 實 際 結算 率 低 於 截 至二 零 二 四 年 十二 月 三 十 一日 止 年 度的 綜 合 財 務 報表 所 採 用 的估 計 結 算 率 ，該 等 差 額 導 致本 期 住 院 服務 收 入 減少 ， 以 及 因 此進 一 步 調 低二 零 二 五 年 上半 年 該 計 劃 涵蓋 的 住 院 服務 收入的估計結算率所致。 本 公 司仍 正 落 實 本 集團 本期未 經審 核 綜 合 財 務業 績 。 本 公 告所 載 資 料 僅基 於 本 集團 未 經 審 核 綜合 管 理 賬 目及 董 事 會 目 前可 得 資 料 作 出的 初 步 評 估。 有 關 資料 未 經 本 公 司核 數 師 或 本公 司 審 核 委 員會 審 核 或 審 閱， 故 可 能 會作 出 調 整及 撥 備 。 股 東及 潛 在 投 資者 務 請 細 閱 本集 團 中 期 業 績公 告 ， 有 關公 告預期於二零二五年八月 ...

本月底法定/註冊股本總額： HKD 390,000 公司名稱: 宏力醫療管理集團有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09906 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 3,900,000,000 | HKD | | 0.0001 | HKD | | 390,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 3,900,000,000 | HKD | | 0.0001 | HKD | | 390,000 | 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港 ...

Core Viewpoint - Hongli Medical Management (09906) reported a total revenue of 769 million yuan for the fiscal year 2024, representing a year-on-year growth of 1.04%, while the net profit attributable to shareholders decreased by 18.69% to 31.15 million yuan [2] Financial Performance - Total revenue for 2024 was 769 million yuan, with a year-on-year increase of 1.04% [2] - Net profit attributable to shareholders was 31.15 million yuan, down 18.69% compared to the previous year [2] - Operating cash flow net amount was 83.34 million yuan, a decrease of 8.97% year-on-year [24] - Basic earnings per share were 0.06 yuan, and the weighted average return on equity was 5.53%, down 1.44 percentage points from the previous year [2][20] Valuation Metrics - As of April 29, the price-to-earnings ratio (TTM) was approximately 27.47 times, the price-to-book ratio (TTM) was about 1.49 times, and the price-to-sales ratio (TTM) was around 1.11 times [2] Revenue Composition - Revenue composition for 2024 included: - Comprehensive medical services: 456.4 million yuan - Pharmaceutical sales: 308.9 million yuan - Postpartum care services: 3.4 million yuan [16] Asset and Liability Changes - As of the end of 2024, accounts receivable increased by 101.48%, while the proportion of right-of-use assets decreased by 28% [35] - Long-term borrowings decreased by 42.75%, and accounts payable decreased by 19.12% [38] - The current ratio was 1.01, and the quick ratio was 0.91 [42]

Financial Performance - Honliv Healthcare reported a revenue increase of 15% year-over-year, reaching HKD 1.2 billion for the fiscal year 2024[2]. - The company achieved a net profit margin of 10%, translating to a net profit of HKD 120 million for the same period[2]. - Future guidance estimates a revenue growth of 12% for the next fiscal year, projecting revenues of approximately HKD 1.34 billion[2]. - The total comprehensive income for the year ended December 31, 2024, was RMB 768.7 million, an increase of 1.1% compared to RMB 760.5 million for the year ended December 31, 2023[13][21]. - Total revenue for 2024 reached RMB 768.7 million, with treatment and comprehensive medical services accounting for 59.4% and drug sales for 40.2%[32]. - Drug sales revenue grew by 4.7% to RMB 308.9 million in 2024, up from RMB 294.9 million in 2023, primarily due to increased outpatient drug sales[24]. - Outpatient medical service revenue rose by 8.0% from RMB 402.6 million to RMB 434.7 million, driven by an increase in outpatient visits and per-visit costs[33]. - Inpatient medical service revenue decreased by 7.6% from RMB 357.9 million to RMB 330.6 million, primarily due to a reduction in inpatient visits and per-visit costs[33]. - Cost of sales increased by 4.3% from RMB 615.7 million to RMB 642.0 million, mainly due to higher pharmaceutical costs and depreciation[34]. - Gross profit decreased by 12.5% from RMB 144.8 million to RMB 126.7 million, with gross margin declining from 19.0% to 16.5%[35]. - Administrative expenses increased by 5.5% from RMB 72.4 million to RMB 76.4 million, primarily due to higher depreciation and amortization expenses[38]. - Net profit decreased by 18.7% from RMB 38.7 million to RMB 31.5 million, with net profit margin declining from 5.1% to 4.1%[41]. Operational Efficiency - Management highlighted a focus on improving operational efficiency, aiming for a 5% reduction in operational costs by the end of 2025[2]. - The company is focusing on cost control and efficiency improvements, including standardizing clinical pathways and integrating supply chains[25]. - The company aims to optimize patient admission structures based on DRG data to improve cost-effectiveness and resource utilization[25]. - The company is committed to improving operational efficiency and service quality in response to increasing competition and patient demand in the healthcare market[20]. Market Expansion and Strategy - Honliv Healthcare plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share over the next three years[2]. - The company is exploring potential acquisitions to diversify its service offerings, with a budget of HKD 200 million allocated for this purpose[2]. - Future strategies include advancing smart hospital construction and enhancing key specialty development to align with industry trends[30]. - The company aims to leverage technological breakthroughs and innovative models to drive growth in the evolving Chinese healthcare market[15]. - The company is responding to the dual pressures of policy reform and demand upgrades by enhancing its competitiveness through specialization, service innovation, and technological breakthroughs[20]. Patient and Service Metrics - User data indicated a growth in active patients by 20%, totaling 150,000 active patients by the end of 2024[2]. - The total number of inpatient visits was 52,940, a decrease of 3.4% from 54,795 in the previous year[22]. - The total number of outpatient visits increased by 2.8% to 1,440,183 from 1,400,791 in the previous year[22]. - Outpatient visits increased by 2.8% to 1,440,183 in 2024, while inpatient visits decreased by 3.4% to 52,940[23]. - The company has launched a new telehealth service, expecting to attract an additional 30,000 users within the first year[2]. Governance and Compliance - Honliv Healthcare's board of directors emphasized the importance of corporate governance and compliance with the latest regulations to maintain investor confidence[2]. - The group emphasizes compliance with regulatory requirements and continues to strengthen internal control compliance management[80]. - The company has established a compliant pollutant control system to meet relevant legal requirements regarding environmental protection[74]. - The company has adopted a standard code of conduct for securities trading by directors[170]. Employee and Shareholder Information - The total number of full-time employees as of December 31, 2024, was 1,955, a decrease from 1,969 employees as of December 31, 2023[65]. - Employee costs for the fiscal year 2024 were approximately RMB 210.9 million, compared to RMB 217.5 million for the fiscal year 2023[65]. - The company raised approximately HKD 264.8 million from the global offering by issuing 150,000,000 shares at HKD 2.10 per share[67]. - As of December 31, 2024, the unutilized net proceeds from the global offering amounted to HKD 69.2 million[68]. - The group did not recommend the distribution of a final dividend for the year ending December 31, 2024[82]. Share Option and Incentive Plans - The company has a share option plan approved on June 17, 2020, which is valid for ten years[119]. - The share option plan allows the company to grant options to selected participants as an incentive for their contributions[120]. - The maximum number of shares that can be issued under the share option plan is capped at 30% of the company's issued share capital[124]. - The general limit for shares that can be issued under the share option plan is set at 10%, equivalent to 60,000,000 shares[124]. - The company adopted the 2022 Restricted Share Unit Plan on August 22, 2022, to recognize and incentivize participants for their contributions[134]. - The 2023 Restricted Share Unit Plan was adopted on May 9, 2023, aimed at recognizing and incentivizing employees of acquired entities[147]. Financial Position and Cash Flow - Cash and cash equivalents increased to approximately RMB 258.5 million from RMB 239.8 million, with bank loans slightly decreasing from RMB 138.0 million to RMB 137.0 million[42]. - The net cash used in investing activities decreased from RMB 88.8 million for the year ended December 31, 2023, to RMB 51.4 million for the year ending December 31, 2024, primarily due to a reduction in expenditures for updating facilities and purchasing equipment by RMB 37.4 million[55]. - The net cash used in financing activities decreased from RMB 19.1 million for the year ended December 31, 2023, to RMB 13.3 million for the year ending December 31, 2024, mainly due to new borrowings of RMB 156.7 million and repayments of borrowings and related interest of RMB 168.4 million[56]. - As of December 31, 2024, the debt-to-asset ratio was 40.6%, down from 43.5% as of December 31, 2023[59]. Audit and Governance Structure - The independent auditor for the year ending December 31, 2024, was PwC, with total fees amounting to RMB 1.95 million[181]. - The audit committee consists of three independent non-executive directors as of the date of the report[165]. - The company has established a remuneration committee responsible for evaluating the performance of directors and senior management, which includes three independent non-executive directors[166]. - The company has a nomination committee that includes one executive director and three independent non-executive directors, responsible for identifying candidates for the board and senior management[167].

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 768,725,000, representing a 1.1% increase from RMB 760,527,000 in 2023[2] - Gross profit decreased by 12.5% to RMB 126,692,000 from RMB 144,844,000 in the previous year[2] - Profit attributable to owners of the company was RMB 31,151,000, down 18.7% from RMB 38,310,000 in 2023[2] - Basic and diluted earnings per share decreased by 14.3% to RMB 0.06 from RMB 0.07[2] - Operating profit for the year was RMB 50,421,000, a decline from RMB 57,445,000 in 2023[4] - The net profit attributable to the company's owners for the year ended December 31, 2024, was RMB 31,151 thousand, down from RMB 38,310 thousand in 2023, a decrease of about 18.5%[22] - Basic earnings per share for 2024 was RMB 0.06, compared to RMB 0.07 in 2023, representing a decline of approximately 14.3%[22] - Net profit decreased by 18.7% from RMB 38.7 million in 2023 to RMB 31.5 million in 2024, resulting in net profit margins of 5.1% and 4.2% respectively[55] Revenue Breakdown - Revenue from medical services was RMB 456,442 thousand in 2024, slightly down from RMB 465,598 thousand in 2023, indicating a decrease of about 3.3%[20] - Pharmaceutical sales increased to RMB 308,861 thousand in 2024 from RMB 294,929 thousand in 2023, reflecting a growth of approximately 4.7%[20] - Outpatient medical service revenue rose by 8.0% from RMB 402.6 million in 2023 to RMB 434.7 million in 2024, driven by an increase in outpatient patient visits and average fees[48] - Inpatient medical service revenue decreased by 7.6% from RMB 357.9 million in 2023 to RMB 330.6 million in 2024, attributed to a decline in inpatient patient visits and average fees[48] Assets and Liabilities - Total assets increased slightly to RMB 974,003,000 from RMB 968,709,000[10] - Total liabilities decreased to RMB 395,080,000 from RMB 421,262,000[10] - Current liabilities decreased to RMB 380,403,000 from RMB 395,465,000[10] - The group's total liabilities decreased to RMB 100,666 thousand in 2024 from RMB 124,461 thousand in 2023, a reduction of approximately 19.1%[26] - The company's debt-to-asset ratio as of December 31, 2024, was 40.6%, down from 43.5% as of December 31, 2023[72] Cash Flow - The net cash generated from operating activities decreased from RMB 91.6 million for the year ended December 31, 2023, to RMB 83.3 million for the year ended December 31, 2024, primarily due to slower collection of receivables from the medical insurance bureau[67] - The net cash used in investing activities decreased from RMB 88.8 million for the year ended December 31, 2023, to RMB 51.4 million for the year ended December 31, 2024, mainly due to a reduction in expenditures for facility upgrades and equipment purchases by RMB 37.4 million[68] - The net cash used in financing activities decreased from RMB 19.1 million for the year ended December 31, 2023, to RMB 13.3 million for the year ended December 31, 2024, due to new borrowings of RMB 156.7 million and repayments of borrowings and related interest totaling RMB 168.4 million[69] Operational Metrics - Total inpatient visits decreased by 3.4% to 52,940 for the year ending December 31, 2024, compared to 54,795 for the previous year[34] - The number of outpatient visits increased by 2.8% to 1,440,183 for the year ending December 31, 2024, compared to 1,400,791 for the previous year[35] - Outpatient average cost increased by 5.0% to RMB 301.9 for the year ending December 31, 2024, compared to RMB 287.4 for the previous year[34] - The average length of hospital stay increased by 2.0% to 9.5 days for the year ending December 31, 2024, compared to 9.3 days for the previous year[35] Corporate Governance - The company has adopted corporate governance codes and complied with all applicable provisions, except for the separation of roles between the Chairman and CEO as stipulated in the corporate governance code[78] - The company has appointed Mr. Qin Yan as both Chairman and CEO, believing his leadership will effectively guide business decisions and strategies[79] - The Audit Committee, consisting of three independent non-executive directors, has reviewed the consolidated financial statements for the year ending December 31, 2024, and found them to be prepared in accordance with applicable accounting standards[81] - The company has adopted a standard code of conduct for directors regarding securities trading, which has been confirmed as adhered to by all directors during the reporting period[80] - The company has made changes to the Nomination Committee to enhance corporate governance and meet new gender diversity requirements effective July 1, 2025[88] Future Plans and Strategies - The company is focusing on enhancing competitiveness through specialized services, service innovation, and technological breakthroughs in response to market pressures and opportunities[31] - Future plans include advancing tiered evaluation, smart hospital construction, and specialized treatment center development[42] - The company aims to strengthen cost control and risk management in response to DRG/DIP medical insurance payment policies[45] - The company is adapting to changes in the economic environment by optimizing cost structures and improving treatment efficiency[30] Social Responsibility - The company actively engages in social responsibility initiatives, including free lung nodule screening activities[41] - The company focuses on integrating medical resources and enhancing collaborative development for sustainable growth[45] Shareholder Information - The company has not declared any dividends for the year ending December 31, 2024[27] - The company will not recommend the payment of a final dividend for the year ending December 31, 2024[84] - The annual performance announcement will be published on the company's website and the Hong Kong Stock Exchange website, with the annual report to be sent to shareholders in due course[85] - The company will hold its annual general meeting on June 13, 2025, with details to be provided to shareholders[86] - The company will suspend the registration of share transfers from June 10, 2025, to June 13, 2025, to determine eligibility for attending the annual general meeting[87] Miscellaneous - The company has not engaged in any purchases, sales, or redemptions of its listed securities during the year ended December 31, 2024[76] - There were no significant events occurring after the reporting period as of the announcement date[77] - The company has obtained 60 scientific and technological achievements, including practical information management systems[40] - The company's auditor, PwC, has confirmed that the figures in the consolidated financial statements are consistent with the audited financial statements for the year[82] - The reporting period ends on December 31, 2024, as per the company's announcement[94] - The company has adopted a restricted share unit plan on May 9, 2023, to incentivize performance among directors[94]